APA (7th ed.) Citation

KH, L., JC, R., A, X., ST, K., C, V., C, B., . . . KC, W. (2022). P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nature cancer, 3(7), 837. https://doi.org/10.1038/s43018-022-00394-x

Chicago Style (17th ed.) Citation

KH, Lin, et al. "P2RY2-AKT Activation Is a Therapeutically Actionable Consequence of XPO1 Inhibition in Acute Myeloid Leukemia." Nature Cancer 3, no. 7 (2022): 837. https://doi.org/10.1038/s43018-022-00394-x.

MLA (9th ed.) Citation

KH, Lin, et al. "P2RY2-AKT Activation Is a Therapeutically Actionable Consequence of XPO1 Inhibition in Acute Myeloid Leukemia." Nature Cancer, vol. 3, no. 7, 2022, p. 837, https://doi.org/10.1038/s43018-022-00394-x.